AKBA

Akebia Therapeutics, Inc. (AKBA) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2025. Akebia Therapeutics is a commercial-stage biopharmaceutical company focused on kidney disease. The quarter marked the first full quarter of U.S. commercial sales for Vafseo (vadadustat), which entered the market in January 2025. Concurrently, the company's legacy product, Auryxia (ferric citrate), lost U.S. patent exclusivity in March 2025, leading to the launch of an authorized generic version.

Key Financial Metrics

Revenue Breakdown: Product revenue was $55.8 million, driven by $12.0 million from Vafseo and $43.8 million from Auryxia (including authorized generic sales). License and collaboration revenue was $1.5 million.

Cash Flow: Net cash used in operating activities was $13.6 million. Net cash provided by financing activities was $74.9 million, primarily due to a $10.0 million debt drawdown and $64.9 million in equity proceeds.

Material Changes vs. Prior Period

• Profitability Turnaround: The company reported a net income of $6.1 million in Q1 2025, a significant improvement from a net loss of $18.0 million in Q1 2024. This was driven by a 76% increase in total revenue and the elimination of $9.0 million in intangible asset amortization expense that occurred in the prior year.
• Revenue Growth: Total revenue increased by $24.7 million (76%) year-over-year, primarily due to the commercial launch of Vafseo and increased Auryxia sales volumes prior to exclusivity loss.
• Interest Expense: Interest expense increased to $7.8 million from $2.5 million in the prior year. This increase is largely attributable to non-cash interest expense of $5.4 million related to the settlement royalties liability from the Vifor Termination Agreement.
• Balance Sheet Strength: Cash and cash equivalents more than doubled from $51.9 million at year-end 2024 to $113.4 million, bolstered by a public offering and ATM sales in the quarter.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Liquidity: Management believes current cash resources and expected revenues are sufficient to fund operations for at least twelve months from the filing date.
• Auryxia: Following the loss of exclusivity (LoE) in March 2025, the company expects revenue declines but anticipates a slower decline than typical LoE scenarios due to the ESRD bundled payment dynamics and the introduction of an authorized generic.
• Vafseo: The company is focused on expanding Vafseo sales to large dialysis organizations and pursuing label expansion for non-dialysis dependent CKD patients.

Key Risks and Contingencies:

• Internal Control Material Weakness: The company identified a material weakness in internal controls over financial reporting related to inventory accounting and sales forecasting as of December 31, 2024. Remediation efforts are ongoing.
• Debt Covenants: The BlackRock Credit Agreement requires maintaining either a minimum cash balance of $15.0 million or trailing twelve-month revenue of $150.0 million. Failure to meet these could trigger an event of default.
• Regulatory & Legal: Risks include potential FDA delays for label expansion, ongoing patent opposition proceedings in India and Europe, and the impact of government funding cuts on FDA operations.
• Supply Chain: Reliance on third-party manufacturers, including facilities in China, exposes the company to geopolitical and trade policy risks.

Investor Verification Checklist

• Inventory Valuation: Verify the remediation of the material weakness regarding inventory accounting and the accuracy of excess inventory reserves, given the recent launch of Vafseo and LoE of Auryxia.
• Debt Covenants: Monitor monthly compliance with the BlackRock Credit Agreement covenants (cash balance vs. revenue thresholds).
• Auryxia Revenue Trajectory: Track the rate of revenue decline for Auryxia post-LoE and the market share capture of the authorized generic versus third-party generics.
• Vafseo Adoption: Assess the speed of Vafseo adoption by major dialysis organizations (DaVita, Fresenius, USRC) and the impact of the ESRD bundled payment reimbursement model.
• Settlement Royalty Liability: Review the assumptions used to calculate the $58.0 million settlement royalties liability and the associated high effective interest rate (41.0%).